Global cord blood corporation reports financial results for the first quarter of fiscal 2022

1q22 added 19,673 new subscribers revenues up 12.2% yoy to rmb315.2 million ($48.8 million) gross profit up 12.6% yoy to rmb267.3 million ($41.4 million) operating income up 17.3% yoy to rmb156.6 million ($24.2 million) non-gaap operating income up 15.5% yoy to rmb168.5 million ($26.1 million) conference call to be held on august 31, 2021, at 8:00 a.m. et hong kong, aug. 30, 2021 /prnewswire/ -- global cord blood corporation (nyse: co) ("gcbc" or the "company"), china's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended june 30, 2021.
CO Ratings Summary
CO Quant Ranking